| [1] |
W Pacak K, Eisenhofer G, Grossman A. The incidentally discovered adrenal mass[J]. N Engl J Med, 2007, 356(19): 2005.
|
| [2] |
Muth A, Hammarstedt L, Hellström M, et al. Cohort study of patients with adrenal lesions discovered incidentally[J]. Br J Surg, 2011, 98(10): 1383-1391.
|
| [3] |
Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal incidentaloma[J]. Endocr Rev, 2020, 41(6): 775-820.
|
| [4] |
Azoury SC, Nagarajan N, Young A, et al. Computed tomography in the management of adrenal tumors: does size still matter?[J]. J Comput Assist Tomogr, 2017, 41(4): 628-632.
|
| [5] |
Dinnes J, Bancos I, Ferrante di Ruffano L, et al. Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis[J]. Eur J Endocrinol, 2016, 175(2): R51-R64.
|
| [6] |
Boland GW, Lee MJ, Gazelle GS, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature[J]. AJR Am J Roentgenol, 1998, 171(1): 201-204.
|
| [7] |
Peña CS, Boland GW, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT[J]. Radiology, 2000, 217(3): 798-802.
|
| [8] |
Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies[J]. Clin Radiol, 2012, 67(1): 38-46.
|
| [9] |
Corwin MT, Remer EM. Adrenal washout CT: point-not useful for characterizing incidentally discovered adrenal nodules[J]. AJR Am J Roentgenol, 2021, 216(5): 1166-1167.
|
| [10] |
Corwin MT, Badawy M, Caoili EM, et al. Incidental adrenal nodules in patients without known malignancy: prevalence of malignancy and utility of washout CT for characterization-a multiinstitutional study[J]. AJR Am J Roentgenol, 2022, 219(5): 804-812.
|
| [11] |
Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status[J]. AJR Am J Roentgenol, 2002, 179(3): 559-568.
|
| [12] |
Schieda N, Al Dandan O, Kielar AZ, et al. Pitfalls of adrenal imaging with chemical shift MRI[J]. Clin Radiol, 2014, 69(11): 1186-1197.
|
| [13] |
Haider MA, Ghai S, Jhaveri K, et al. Chemical shift MR imaging of hyperattenuating (>10 Hu) adrenal masses: does it still have a role?[J]. Radiology, 2004, 231(3): 711-716.
|
| [14] |
Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study[J]. Eur J Endocrinol, 2012, 166(4): 669-677.
|
| [15] |
Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas[J]. J Clin Endocrinol Metab, 2014, 99(12): 4462-4470.
|
| [16] |
Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 396-405.
|
| [17] |
Jędrusik P, Symonides B, Lewandowski J, et al. The effect of antihypertensive medications on testing for primary aldosteronism[J]. Front Pharmacol, 2021, 12: 684111.
|
| [18] |
Gruber LM, Strajina V, Bancos I, et al. Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis[J]. Gland Surg, 2020, 9(2): 362-371.
|
| [19] |
Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery[J]. J Clin Endocrinol Metab, 2019, 104(5): 1386-1393.
|
| [20] |
van Berkel A, Lenders JWM, Timmers HJLM. Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma[J]. Eur J Endocrinol, 2014, 170(3): R109-R119.
|
| [21] |
Perry CG, Sawka AM, Singh R, et al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma[J]. Clin Endocrinol, 2007, 66(5): 703-708.
|
| [22] |
Fassnacht M, Tsagarakis S, Terzolo M, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the european network for the study of adrenal tumors[J]. Eur J Endocrinol, 2023, 189(1): G1-G42.
|
| [23] |
Rowe NE, Kumar RM, Schieda N, et al. Canadian urological association guideline: diagnosis, management, and followup of the incidentally discovered adrenal mass[J]. J De L'association Des Urol Du Can, 2023, 17(2): 12-24.
|
| [24] |
Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1, 049 consecutive adrenal masses in patients with no known malignancy[J]. AJR Am J Roentgenol, 2008, 190(5): 1163-1168.
|
| [25] |
Corwin MT, Chalfant JS, Loehfelm TW, et al. Incidentally detected bilateral adrenal nodules in patients without cancer: is further workup necessary?[J]. AJR Am J Roentgenol, 2018, 210(4): 780-784.
|
| [26] |
Goh Z, Phillips I, Hunt PJ, et al. Three-year follow up of adrenal incidentalomas in a New Zealand centre[J]. Intern Med J, 2020, 50(3): 350-356.
|
| [27] |
Collienne M, Timmesfeld N, Bergmann SR, et al. Adrenal incidentaloma and subclinical Cushing's syndrome: a longitudinal follow-up study by endoscopic ultrasound[J]. Ultraschall Med, 2017, 38(4): 411-419.
|
| [28] |
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: european society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors[J]. Eur J Endocrinol, 2016, 175(2): G1-G34.
|